Edition:
United Kingdom

Aptevo Therapeutics Inc (APVO.OQ)

APVO.OQ on NASDAQ Stock Exchange Global Select Market

3.98USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
138,905
52-wk High
$4.48
52-wk Low
$1.18

Chart for

About

Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company... (more)

Overall

Beta: --
Market Cap(Mil.): $57.83
Shares Outstanding(Mil.): 21.42
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma

* APTEVO THERAPEUTICS ANNOUNCES PLANS TO CONDUCT PHASE 2 STUDY OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA

28 Nov 2017

BRIEF-Aptevo Therapeutics files mixed shelf of up to $150 mln

* Aptevo Therapeutics Inc files for mixed shelf of up to $150 million - SEC filing‍​ Source text for Eikon: (http://bit.ly/2hvzJMI) Further company coverage:

13 Nov 2017

BRIEF-Aptevo Therapeutics reports third quarter 2017 financial results

* Aptevo Therapeutics reports third quarter 2017 financial results

09 Nov 2017

BRIEF-Aptevo Therapeutics and Alligator Bioscience announced further details of collaboration on ALG.APV-527​

* Aptevo Therapeutics Inc - ‍ co, Alligator Bioscience announced further details of companies' collaboration on ALG.APV-527​ Source text for Eikon: Further company coverage:

24 Oct 2017

BRIEF-APTEVO THERAPEUTICS ‍AMENDS TERMS OF CREDIT AGREEMENT

* APTEVO THERAPEUTICS INC - ‍AMENDED TERMS OF A CREDIT AGREEMENT INITIALLY EXECUTED WITH MIDCAP FINANCIAL TRUST IN AUGUST 2016​

28 Sep 2017

BRIEF-Aptevo Therapeutics and MorphoSys ends joint agreement to develop and commercialize MOR209/ES414

* Aptevo Therapeutics and MorphoSys end joint development and commercialization agreement for MOR209/ES414

31 Aug 2017

BRIEF-Aptevo Therapeutics signs agreement for up to $74.5 mln to sell Hyperimmune Commercial Products

* Aptevo Therapeutics signs agreement for up to $74.5 million to sell hyperimmune commercial products

31 Aug 2017

BRIEF-Aptevo and Alligator Bioscience start IND-enabling development activities immunotherapy drug

* Aptevo Therapeutics and Alligator Bioscience commence IND-enabling development activities for new bispecific immunotherapy candidate ALG.APV-527 Source text for Eikon: Further company coverage:

17 Aug 2017

BRIEF-Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy

* Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy

20 Jul 2017

BRIEF-Aptevo Therapeutics' unit, CMC ICOS Biologics enter non-exclusive amended and restated commercial supply agreement

* Aptevo Therapeutics- on June 17, unit and CMC ICOS biologics entered non-exclusive amended and restated commercial supply agreement - SEC filing

22 Jun 2017

Earnings vs. Estimates